|Bid||1,942.00 x 0|
|Ask||1,941.50 x 0|
|Day's Range||1,932.00 - 1,949.00|
|52 Week Range||1,470.00 - 2,025.00|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||29.89|
|Earnings Date||Jan. 27, 2022 - Jan. 31, 2022|
|Forward Dividend & Yield||50.00 (2.56%)|
|Ex-Dividend Date||Mar. 30, 2022|
|1y Target Est||N/A|
BOTHELL, Wash. & TOKYO, October 12, 2021--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869). The cohort is evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or me
TOKYO & BOTHELL, Wash., September 27, 2021--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved PADCEV® (enfortumab vedotin) for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. The New Drug Application received priority review.
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.